Alimta Mesothelioma Indication: Response Not Acceptable Endpoint, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Response is not an acceptable primary endpoint for approval in mesothelioma, FDA said in review documents for Lilly’s oncologic agent Alimta.
You may also be interested in...
The significant survival benefit seen with Alimta in Lilly’s sole pivotal mesothelioma trial appears to have obviated FDA’s need for efficacy data from a second study.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011